PDGFRA exon 12 mutations in GIST are imatinib-sensitive. Imatinib 400 mg/day is standard...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PDGFRA-EXON12-GIST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GIST |
| Sources | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-PDGFRA |
|---|---|
| Variant | exon 12 mutation (juxtamembrane domain — V561D most common; rare <2% GIST) |
| Disease | DIS-GIST |
| ESCAT tier | IB |
| Recommended combinations | imatinib 400 mg/day (1L advanced/metastatic) |
| Evidence summary | PDGFRA exon 12 mutations in GIST are imatinib-sensitive. Imatinib 400 mg/day is standard 1L — response rates comparable to KIT exon 11 and PDGFRA non-D842V exon 18. Rare genotype (<2% of GIST). |
Notes
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST.
Used By
No reverse references found in the YAML corpus.